Thymic Carcinoma Clinical Trial
Official title:
Clinical Study of Envolizumab Combined With Radiotherapy for Neoadjuvant Treatment of Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.
For patients with locally advanced thymic carcinoma, it is often difficult to perform radical resection. Numerous studies have reported that neoadjuvant therapy can improve the surgical resection rate of thymic tumors by reducing the extent of tumor invasion and eliminating small metastatic lesions, thereby improving patient survival. However, the efficacy of neoadjuvant immunotherapy combined with chemotherapy is limited. This study intends to conduct a single-arm, phase II clinical trial of neoadjuvant immunotherapy combined with radiotherapy for locally advanced thymic carcinoma to verify the feasibility and safety of neoadjuvant immunotherapy combined with radiotherapy. Meanwhile, the investigators evaluate the pathological remission of postoperative specimens to provide recommendations for establishing pathological evaluation criteria for neoadjuvant therapy for thymic carcinoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
Completed |
NCT02623127 -
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
Active, not recruiting |
NCT02364076 -
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
|
Phase 2 | |
Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03449173 -
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
|
Phase 2 | |
Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT01364727 -
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
|
Phase 2 | |
Suspended |
NCT03463460 -
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
|
Phase 2 | |
Completed |
NCT00010257 -
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
|
Phase 2 | |
Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
Active, not recruiting |
NCT03583086 -
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03517488 -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00198133 -
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
Recruiting |
NCT03170804 -
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
|
N/A | |
Recruiting |
NCT05667948 -
Molecular Analysis and Treatment Options of Thymic Malignancies
|
||
Terminated |
NCT01011439 -
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
|
Phase 2 | |
Terminated |
NCT01143545 -
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
|
Phase 1 | |
Completed |
NCT02307500 -
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
|
Phase 2 | |
Active, not recruiting |
NCT01025089 -
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
|
Phase 2 |